Three times as many patients achieved a durable hemoglobin response with nipocalimab versus placebo in the Phase 2/3 ENERGY trial, and that single number explains why the FDA’s August 24 approval of IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia carries real clinical weight. wAIHA is a rare, life-threatening disease in which IgG autoantibodies destroy red blood cells, and patients have long cycled through corticosteroids and broad immunosuppressants, neither of which targets the pathogenic IgG driving the destruction. IMAAVY is a selective FcRn blocker, designed to reduce circulating IgG autoantibodies while preserving B-cell function, and this approval marks the first time a therapy has been proven safe and effective specifically for wAIHA.
The data from ENERGY (NCT04119050) are worth examining closely. The primary endpoint, durable hemoglobin response, was defined stringently: Hgb at or above 10 g/dL and at least a 2 g/dL increase from baseline sustained for 28 or more days, achieved by Week 16, without rescue therapy. Hitting that bar three times more often than placebo at 24 weeks is a meaningful separation in a 115-patient randomized, double-blind, placebo-controlled trial. The speed signal is also notable: a mean 1 g/dL Hgb increase appeared at Week 1 in the IMAAVY arm, with a median time to first response of 4.1 weeks versus 12.1 weeks for placebo. On the fatigue side, the 3.5-point FACIT-Fatigue advantage over placebo at Week 24 landed with a 95% confidence interval of 0.64 to 6.39, a statistically plausible but modest margin that regulators accepted as a key secondary endpoint, albeit one the trial’s statistical plan labels descriptive.
The safety profile carries its own context. The most common adverse reactions at the approved 30 mg/kg intravenous every-four-weeks dose were peripheral edema, diarrhea, and fever, each occurring in at least 10% of patients. Johnson and Johnson notes the profile is consistent with IMAAVY’s established record in generalized myasthenia gravis, where it received FDA approval in April 2025. That prior approval matters commercially: J&J already has a functioning infusion infrastructure, patient support infrastructure, and prescriber familiarity with FcRn blockade across a neuromuscular indication, which compresses the commercial lift for this second label considerably.
What to watch now is real-world hemoglobin durability beyond the 24-week double-blind window. The ENERGY open-label extension is ongoing, and whether that 3x response advantage holds at 48 or 72 weeks will determine whether IMAAVY earns a durable place in the wAIHA treatment sequence or functions as a bridge therapy for patients cycling off steroids. The ASH-endorsed corticosteroid-first standard is deeply entrenched, and post-approval durability data, not the approval itself, will drive uptake among hematologists deciding when to reach for a targeted agent.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
